Skip to main content

Table 1 Baseline characteristics of patients with UC treated with ADA or IFX

From: Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)

  Adalimumab (ADA) (n=111) Infliximab (IFX) (n=282) P-value
Age (y) 42.95 ±14.09 41.43 ±13.40 0.3191
Age at diagnosis (y) 34.42 ±13.72 32.68 ±12.74 0.2352
BMI (kg/m2) 25.23 ±4.11 25.14 ±5.17 0.8771
Female gender 75 (67.57) 167 (59.22) 0.1256
Caucasian 61 (54.95) 198 (70.21) 0.0025
Active smoking 6 (5.61) 28 (10.11) <0.001
Presence of comorbidities 43 (38.74) 110 (39.29) 0.9204
Disease extension
Pancolitis 71 (64.55) 173 (61.57) 0.8599
Left sided colitis 33 (30.00) 91 (32.38)
Distal colitis 6 (5.45) 17 (6.05)
Extraintestinal manifestations (EIM) 46 (42.59) 91 (32.50) <0.001
Rheumatological 31 (28.70) 60 (21.43) 0.002
Dermatological 7 (6.48) 14 (5.00) 0.127
Hepatic 7 (6.48) 9 (3.21) 0.617
Ocular 0 3 (1.07) 0.5633
Thromboembolic events 3 (2.78) 8 (2.86) 0.132
Corticosteroids at baseline 68 (61.82) 209 (74.64) <0.001
Concomitant azathioprine 65 (58.56) 234 (82.98) <0.0001
Time between diagnosis and onset of anti-TNF (y) 6.33 ±5.65 5.73 ±5.39 0.240
Previous use of biological therapy 36 (32.43) 40 (14.23) 0.643
Clinical disease activity
Remission 2 (1.94) 6 (2.21) 0.2853
Mild 18 (17.48) 28 (10.33)
Moderate 65 (63.11) 179 (66.05)
Severe 18 (17.48) 58 (21.40)
Mayo endoscopic subscore
0 - remission 3 (2.91) - 0.002
1 - mild 7 (6.79) 8 (2.94)
2 - moderate 27 (26.20) 109 (40.07)
3 - severe 66 (64.08) 155 (56.98)
  1. Data presented as mean ± SD and n (%). BMI Body mass index. *Calculated by Student t test or Pearson, χ2 or Fisher´s exact test